Raymond Kaempfer

This inventor holds 12 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Atox Bio Ltd., Hadasit Medical Research Services and Development Company. Active years: 1998-2023.

USPTO Granted Patents = 12

% Patents Active = 75.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 19(Granted Patents)

Location History:

Jersualem, IL (2006)
Jerusalem, IL (1998 - 2023)

Company Filing History:

11 out of 911

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Hadasit Medical Research Services and Development Company

patents

where one patent can have more than one assignee

Years Active: 1998-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11613565 - Isolated peptides derived from the B7 ligand dimer interface and uses thereof (2023-03-28),

2. 11304989 - Peptides for use in the treatment of viral infections (2022-04-19),

3. 10584157 - Isolated peptides derived from the B7 ligand dimer interface and uses thereof (2020-03-10),

4. 10280209 - Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 (2019-05-07),

5. 9963497 - Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 (2018-05-08),

6. 9567367 - Synthetic peptides for treatment of bacterial infections (2017-02-14),

7. 9546207 - Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof (2017-01-17),

8. 8535672 - Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof (2013-09-17),

9. 7189398 - Broad spectrum pyrogenic exotoxins antagonists and vaccines (2007-03-13),

10. 7060277 - Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins (2006-06-13),

11. 7049133 - Regulation of gene expression through manipulation of mRNA splicing and its uses (2006-05-23),

12. 5837467 - Method for predicting the response to treatment with BCG of superficial (1998-11-17),

Title: The Innovations of Raymond Kaempfer: A Pioneer in Peptide Research

Introduction

Raymond Kaempfer, a prominent inventor based in Jerusalem, Israel, has made significant contributions to the field of peptide research. With a remarkable portfolio of 12 patents, his work primarily focuses on the development of innovative peptides with therapeutic applications. His inventions are paving the way for advancements in medical treatments, particularly in addressing viral infections.

Latest Patents

Among his latest patents, two notable inventions reflect his expertise:

1. **Isolated Peptides Derived from the B7 Ligand Dimer Interface** - This patent discloses peptides that include amino acid residues of the dimer interface of human B7-1 and B7-2. The compositions derived from these peptides and their uses in various biomedical applications are also explored.

2. **Peptides for Use in the Treatment of Viral Infections** - In this insightful patent, Kaempfer discusses peptides, compositions, and methods designed to treat viral pathogen infections. The innovative combinations and kits include the disclosed peptides alongside additional antiviral therapeutic agents.

Career Highlights

Raymond Kaempfer has worked with prestigious organizations, including the Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Atox Bio Ltd. His innovative mindset and research-driven approach have propelled these institutions forward in their respective fields.

Collaborations

Throughout his career, Kaempfer has collaborated with talented colleagues, including Gila Arad and Anat Shirvan. These partnerships have contributed to the creation of cutting-edge solutions and have fostered a collaborative environment conducive to scientific progress.

Conclusion

Raymond Kaempfer’s work exemplifies the intersection of innovation and practicality in medical research. With his impressive patent portfolio and collaborative spirit, he continues to be a significant figure in advancing peptide applications for viral treatments. His contributions not only highlight the potential of peptide research but also inspire future innovations in the field.